Accelerating Lead Optimization Away from Anti-Targets: Navigating the Structural Complexity of Promiscuous ADMET Proteins

Abstract The development of a small molecule suitable for clinical use involves optimization of ligand binding to an identified target protein but also frequently the reduction of binding to a variety of anti-target proteins known to pose translational risk. These anti-targets, often referred to as ADMET proteins, often contain large, highly flexible binding sites, leading to promiscuous binding of small molecules. This property often frustrates efforts to execute structure-based design against these anti-targets. Here, we demonstrate the application of a combination of induced fit docking and free energy perturbation to structurally enable several of the most common anti-targets: cytochrome P450 isoforms 3A4 and 2D6, the hERG ion channel, and PXR. Crucially, the enforcement of a consensus binding mode across a congeneric series allowed for the efficient exploration of a wide range of receptor conformational space. Results are presented for both public retrospective datasets and prospective application in active drug discovery programs.

Authors

Institutions

Publication Details

Journal
Journal of Chemical Theory and Computation
Published
2026-10-22
DOI
https://doi.org/10.1021/acs.jctc.6c01007
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Accelerating Lead Optimization Away from Anti-Targets: Navigating the Structural Complexity of Promiscuous ADMET Proteins

Daigo Inoyama, Steven K. Albanese, Richard A. Friesner, Robert Abel et al.
Journal of Chemical Theory and Computation
Computational Drug Discovery Methods
article

Accelerating Lead Optimization Away from Anti-Targets: Navigating the Structural Complexity of Promiscuous ADMET Proteins

Daigo Inoyama, Steven K. Albanese, Richard A. Friesner, Robert Abel, Andreas Verras, Robert D. Pelletier, Sébastien Campos, Lewis Whitehead, Angela V. Toms, Scott D. Edmondson, Andrew Placzek, Justin A. Caravella, Peter J. Tummino, Edward B. Miller, Tianchuan Xu, Howook Hwang, Kevin DeMarco, Neelu Kaila, Sheetal Kumar, Mee Shelley, Samantha Carreiro, Kyle Konze, Kevin D. Kreutter, Joshua McElwee, Sung-Sau So
article en

Abstract

Abstract The development of a small molecule suitable for clinical use involves optimization of ligand binding to an identified target protein but also frequently the reduction of binding to a variety of anti-target proteins known to pose translational risk. These anti-targets, often referred to as ADMET proteins, often contain large, highly flexible binding sites, leading to promiscuous binding of small molecules. This property often frustrates efforts to execute structure-based design against these anti-targets. Here, we demonstrate the application of a combination of induced fit docking and free energy perturbation to structurally enable several of the most common anti-targets: cytochrome P450 isoforms 3A4 and 2D6, the hERG ion channel, and PXR. Crucially, the enforcement of a consensus binding mode across a congeneric series allowed for the efficient exploration of a wide range of receptor conformational space. Results are presented for both public retrospective datasets and prospective application in active drug discovery programs.

Journal of Chemical Theory and Computation
Schrodinger (United States) (US)
Openalex Percentile: Top 14%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon